These findings suggested that various phenylalkylamines, acting as allosteric CaSR antagonists (calcilytics; e.g., NPS 89636 and NPS 2143) capable of shifting the CaSR response curve to changes in [Ca2+]e54, 64, may be potential AD therapeutics. This evidence concerns the gene CASR and Alzheimer disease.